Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Welcome to the TNL Beta! We are actively improving this experience.

Share Feedback

Source study found

Story checked

Neural signaling protein could be therapeutic target for autism-linked gene deletion (opens in a new tab)

medicalxpress.com · 2026-11-05

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 2 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Two of five check out. Two claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedThe authors suggest inhibiting PSD-95 could be a therapeutic target to reduce seizures and rescue some cognitive ability in people with MEF2C haploinsufficiency or other conditions that decrease MEF2C.View evidenceHide evidence

Why this verdict

The paper profile supports a hedged therapeutic-target interpretation for MEF2C haploinsufficiency syndrome based on mouse rescue experiments. However, the claim extends the implication to people and to 'other conditions that decrease MEF2C,' while the abstract-level limitations state that translational relevance to humans is not addressed and the broader-condition extension is not established in the supplied profile. The therapeutic suggestion is therefore broader than the abstract evidence supports.

1

Study evidence

Knocking down PSD-95 efficiently reduced hyperexcitability phenotypes and seizure susceptibility in MEF2C haploinsufficient mice (abstract statement).

“Knocking down PSD-95 ... efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
2

Study evidence

Pharmacologic disruption of the PSD-95–NMDA receptor interaction efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficient mice.

“or inhibiting the interaction between PSD-95 and NMDA receptors efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
Claim 2 of 5Not coveredMEF2C deletions or mutations are associated with neurological and developmental disorders including autism, epilepsy and Alzheimer's disease, and MEF2C haploinsufficiency is characterized by intellectual disability, autism spectrum disorder and seizures.View evidenceHide evidence

Why this verdict

The abstract profile supports that MEF2C haploinsufficiency syndrome is characterized by intellectual disability, epilepsy/seizures, and ASD-related behaviors. However, the broader statement that MEF2C deletions or mutations are associated with conditions ranging to Alzheimer's disease is not present in the abstract-level profile, so that portion cannot be verified at this evidence depth.

1

Study evidence

MEF2C haploinsufficiency in forebrain excitatory neurons led to elevated PSD-95 levels in mice.

“MEF2C haploinsufficiency in forebrain excitability neurons led to an elevation of postsynaptic density protein 95 (PSD-95) in mice.”
2

Study evidence

MEF2C haploinsufficiency in forebrain excitatory neurons is associated with augmented neuronal excitability in mice.

“augmented neuronal excitability, and increased susceptibility to seizures.”
Claim 3 of 5Not coveredReducing PSD-95 by genetic knockdown or by a drug that inhibits PSD-95 interactions restored novel object recognition and social novelty recognition and brought severe seizures back to the normal range in MEF2C-haploinsufficient mice.View evidenceHide evidence

Why this verdict

The abstract profile supports that PSD-95 knockdown reduced hyperexcitability/seizure susceptibility and improved cognitive behaviors, and that inhibiting the PSD-95–NMDA receptor interaction reduced hyperexcitability phenotypes. But the abstract-level evidence does not verify the named behavioral assays, that both genetic knockdown and the drug/inhibitor restored novel object and social novelty recognition, or that severe seizures were brought 'back to the normal range.' Those specific magnitude and modality details require full-text evidence.

1

Study evidence

Knocking down PSD-95 efficiently reduced hyperexcitability phenotypes and seizure susceptibility in MEF2C haploinsufficient mice (abstract statement).

“Knocking down PSD-95 ... efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
2

Study evidence

Pharmacologic disruption of the PSD-95–NMDA receptor interaction efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficient mice.

“or inhibiting the interaction between PSD-95 and NMDA receptors efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
Claim 4 of 5SupportedA particular signaling protein in the brain could be a therapeutic target for neurological disorders arising from deletion of the autism-linked gene MEF2C, according to a new mouse study published in PNAS.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the headline’s hedged therapeutic-target framing: PSD-95 knockdown and disruption of PSD-95–NMDA receptor interaction reduced hyperexcitability phenotypes in MEF2C-haploinsufficient mice, and PSD-95 knockdown improved cognitive behaviors. The story also notes this is a mouse study, which keeps the headline’s 'could be' framing within the preclinical evidence.

1

Study evidence

Knocking down PSD-95 efficiently reduced hyperexcitability phenotypes and seizure susceptibility in MEF2C haploinsufficient mice (abstract statement).

“Knocking down PSD-95 ... efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
2

Study evidence

Pharmacologic disruption of the PSD-95–NMDA receptor interaction efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficient mice.

“or inhibiting the interaction between PSD-95 and NMDA receptors efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
Claim 5 of 5SupportedThe researchers found elevated PSD-95 levels in the brains of mice with only one copy of MEF2C.View evidenceHide evidence

Why this verdict

The profile explicitly states that MEF2C haploinsufficiency in forebrain excitatory neurons led to elevated PSD-95 in mice. The story’s wording 'in the brains' is somewhat less specific than the profile’s forebrain-excitatory-neuron model, but the core claim is supported.

1

Study evidence

MEF2C haploinsufficiency in forebrain excitatory neurons led to elevated PSD-95 levels in mice.

“MEF2C haploinsufficiency in forebrain excitability neurons led to an elevation of postsynaptic density protein 95 (PSD-95) in mice.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract does not provide quantitative effect sizes, sample sizes, statistical details, exact assays, intervention delivery details, or rigor measures such as randomization/blinding.

    The story’s caveats mention future mechanistic work and new-drug exploration, but they do not acknowledge the lack of abstract-level quantitative and methodological detail. This matters especially for claims about restoration and return to a normal range.

    From in_vivo_animal; in_vivo_animal electrophysiology and seizure susceptibility testing (implied); in_vivo genetic knockdown

5 things the story did carry across
  • MEF2C haploinsufficiency in forebrain excitatory neurons elevates PSD-95 in mice and coincides with increased structural synapses, increased NMDA receptor surface expression, augmented neuronal excitability, and greater seizure susceptibility.
  • Reducing PSD-95 genetically reduced hyperexcitability/seizure-related phenotypes and improved cognitive behaviors in MEF2C-haploinsufficient mice.
  • Inhibition of the PSD-95–NMDA receptor interaction reduced hyperexcitability phenotypes in MEF2C-haploinsufficient mice.
  • The evidence is preclinical and from a mouse model; applicability to humans is not addressed in the abstract.
  • MEF2C haploinsufficiency syndrome is described in the paper profile as involving intellectual disability, epilepsy/seizure phenotypes, and ASD-related behaviors.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalPSD-95 knockdown improves cognitive behaviors in MEF2C haploinsufficient mice (behavioral rescue / therapeutic relevance).in vivo animal behavioral rescueExpand

In plain English

Abstract reports that knocking down PSD-95 significantly improved cognitive behaviors in MEF2C haploinsufficient mice, and the authors propose PSD-95 as a therapeutic target for MEF2C haploinsufficiency syndrome.

Key findings

  • Knocking down PSD-95 significantly improved cognitive behaviors in mice with MEF2C haploinsufficiency (abstract statement).
“Most importantly, knocking down PSD-95 significantly improved cognitive behaviors in mice with MEF2C haploinsufficiency.”
What this piece can’t prove
  • Abstract does not specify the behavioral assays used, sample sizes, statistical analyses, effect sizes, or experimental rigor measures (randomization/blinding).

2 further details could not be confirmed from the summary.

2in vivo animalMEF2C haploinsufficiency in forebrain excitatory neurons elevates PSD-95 and is associated with increased synapse number, NMDA receptor surface expression, neuronal hyperexcitability, and seizure susceptibility in mice (a mechanistic basis for hyperexcitability in MCHS).in vivo animalExpand

In plain English

In a mouse model with MEF2C haploinsufficiency targeted to forebrain excitatory neurons, the authors report elevated postsynaptic density protein 95 (PSD-95). This PSD-95 elevation coincided with an increased number of structural synapses and increased surface expression of NMDA receptors, and was associated with augmented neuronal excitability and greater seizure susceptibility. Interventions that reduced PSD-95 levels or disrupted PSD-95–NMDA receptor interactions reduced hyperexcitability and PSD-95 knockdown improved cognitive behaviors in the MEF2C haploinsufficiency mice.

Key findings

  • MEF2C haploinsufficiency in forebrain excitatory neurons led to elevated PSD-95 levels in mice.
  • PSD-95 elevation coincided with an increased number of structural synapses.
“MEF2C haploinsufficiency in forebrain excitability neurons led to an elevation of postsynaptic density protein 95 (PSD-95) in mice.”
What this piece can’t prove
  • Summary is based solely on the paper abstract; the abstract does not report numerical effect sizes, sample sizes, statistical significance, or detailed assay protocols.

2 further details could not be confirmed from the summary.

3in vivo animalMEF2C haploinsufficiency in forebrain excitatory neurons elevates PSD-95 and is associated with increased synapse number, NMDA receptor surface expression, neuronal hyperexcitability, and seizure susceptibility in mice (a mechanistic basis for hyperexcitability in MCHS).in vivo animal electrophysiology and seizure susceptibility testing (implied)Expand

In plain English

In mice with MEF2C haploinsufficiency in forebrain excitatory neurons, the authors report elevated PSD-95 that coincided with increased structural synapse number, increased surface expression of NMDA receptors, augmented neuronal excitability, and increased seizure susceptibility; reducing PSD-95 levels or inhibiting PSD-95–NMDAR interactions reduced hyperexcitability, and PSD-95 knockdown improved cognitive behaviors.

Key findings

  • MEF2C haploinsufficiency in forebrain excitatory neurons is associated with augmented neuronal excitability in mice.
  • MEF2C haploinsufficiency is associated with increased susceptibility to seizures in mice.
“augmented neuronal excitability, and increased susceptibility to seizures.”
What this piece can’t prove
  • All reported findings are from a mouse model; applicability to human MCHS requires further evidence beyond the abstract.

2 further details could not be confirmed from the summary.

4in vivo animalReducing PSD-95 function (genetic knockdown or disrupting PSD-95–NMDA receptor interaction) reverses hyperexcitability/seizure-related phenotypes in MEF2C haploinsufficient mice (therapeutic mechanism validation).in vivo genetic knockdownExpand

In plain English

In MEF2C haploinsufficient mice, genetic knockdown of PSD-95 reduced hyperexcitability phenotypes and seizure susceptibility; the abstract also reports that PSD-95 knockdown improved cognitive behaviors. The report does not provide quantitative effect sizes, methodological details of the knockdown, or statistical/sample-size information in the abstract.

Key findings

  • Knocking down PSD-95 efficiently reduced hyperexcitability phenotypes and seizure susceptibility in MEF2C haploinsufficient mice (abstract statement).
“Knocking down PSD-95 ... efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
What this piece can’t prove
  • Unclear whether the hyperexcitability rescue and cognitive improvements derive from the same cohorts/experiments or from separate experiments (abstract does not specify).

2 further details could not be confirmed from the summary.

5in vivo animalReducing PSD-95 function (genetic knockdown or disrupting PSD-95–NMDA receptor interaction) reverses hyperexcitability/seizure-related phenotypes in MEF2C haploinsufficient mice (therapeutic mechanism validation).in vivo pharmacologic inhibitionExpand

In plain English

The paper reports that non-genetic inhibition of the PSD-95–NMDA receptor interaction in MEF2C haploinsufficient mice reduced neuronal hyperexcitability and seizure-related phenotypes. The intervention was applied in vivo and assessed using excitability and seizure-susceptibility measures, producing a functional rescue of hyperexcitability at the level reported in the abstract.

Key findings

  • Pharmacologic disruption of the PSD-95–NMDA receptor interaction efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficient mice.
“or inhibiting the interaction between PSD-95 and NMDA receptors efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 40 candidate papers

Candidate

Functional traits explain the enhancement of denitrification by wetland plants

Journal of Plant Ecology · 2026 · Crossref

Source (opens in a new tab)
Candidate

Greenhouse gas emissions and control measures for constructed wetland: A systematic review

Journal of Environmental Management · 2026 · Crossref

Source (opens in a new tab)
Candidate

Capacity building initiatives in orthopaedic outreach: A barrier-strategy mapping tool

Journal of Orthopaedic Reports · 2026 · Crossref

Source (opens in a new tab)
Candidate

Wear Degradation of High-Nitrogen Austenitic Steels for Internal Combustion Engines in Hydrogen-Containing Alternative Fuels

Energies · 2026 · Crossref

Source (opens in a new tab)

And 34 more candidates considered.